- Home
- SILC vs ICUCW Comparison
SILC vs ICUCW Comparison
Compare SILC & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SILC | ICUCW |
|---|---|---|
| Founded | 1987 | N/A |
| Country | Israel | United States |
| Employees | N/A | 18 |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.8M | N/A |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SILC | ICUCW |
|---|---|---|
| Price | $14.15 | $0.01 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 12.6K | N/A |
| Earning Date | 01-29-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $59,509,000.00 | N/A |
| Revenue This Year | $6.48 | N/A |
| Revenue Next Year | $14.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.44 | N/A |
| 52 Week High | $19.37 | N/A |
Technical Indicators
Market Signals| Indicator | SILC | ICUCW |
|---|---|---|
| Relative Strength Index (RSI) | 36.65 | 37.08 |
| Support Level | $14.15 | $0.01 |
| Resistance Level | $14.43 | $0.01 |
| Average True Range (ATR) | 0.42 | 0.00 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 0.00 | 20.00 |
Price Performance
Historical ComparisonAbout SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About ICUCW SeaStar Medical Holding Corporation Warrant
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.